Article Text

Download PDFPDF
679 Prognostic factors in the management of adult granulosa cell tumors of the ovary: a joint MITO-GINECO analysis within the ENGOT rare tumor working group
  1. Alice Bergamini1,
  2. Costanza Saponaro1,
  3. Brunhilde Hanvic2,
  4. Nicolas Chopin2,
  5. Luca Bocciolone1,
  6. Amandine Maulard3,
  7. Gabriella Ferrandina4,
  8. Enora Laas5,
  9. Cormio Gennaro6,
  10. Claire Illac-Vauquelin7,
  11. Marco Carnelli8,
  12. Emeline Meriaux9,
  13. Giovanna Scarfone10,
  14. Cyril Abdeddaim11,
  15. Anna Myriam Perrone12,
  16. Frederic Guyon13,
  17. Dominique Berton14,
  18. Giorgia Mangili1,
  19. Sandro Pignata15 and
  20. Isabelle Ray-Coquard2
  1. 1IRCCS San Raffaele Hospital, Milan, Italy
  2. 2Centre Léon Bérard, Lyon, France
  3. 3Surgery, Gustave Roussy Cancer Center, Villejuif, France
  4. 4Department of Women’s and Children’s Health, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
  5. 5Surgery, Institut Curie, Paris, France
  6. 6Gynecologic Oncology Istituto Tumori Giovanni Paolo II – IRCCS, University of Bari, Bari, Italy
  7. 7Pathology, Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France
  8. 8Obstetrics and Gynecology Department, ASST Papa Giovanni XXIII, Bergamo, Italy
  9. 9Medical Oncology, Centre François Baclesse, Caen, France
  10. 10Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
  11. 11Medical Oncology, Centre Oscar Lambret, Lille, France
  12. 12Department of Obstetrics and Gynecology, Unit of Oncologic Gynecology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
  13. 13Surgery, Institut Bergonié, Bordeaux, France
  14. 14Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes, France
  15. 15Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy


Introduction/Background Adult-type Granulosa Cell Tumors (AGCT) of the ovary account for 5% of ovarian malignancies. Several issues on management remain controversial, due to limited evidence. The aim of this project was to assess the feasibility of pooling existing retrospective data within the collaborative groups of the ENGOT Rare Tumor Working Group and to analyze prognostic factors for survival.

Methodology This study included patients diagnosed with AGCT, registered within GINECO/TMRG and MITO groups databases, after anonymized data pooling. Peritoneal staging was considered done if peritoneal biopsies, omentectomy or peritonectomy were performed during first/restaging surgery. Conservative surgery comprised cystectomy or unilateral salpingo-oophorectomy.Clinicopathological variables were evaluated for association with relapse and death. Survival curves were calculated using Kaplan-Meier method and compared with log-rank test.

Results 585 patients were included; 336(57.4%) and 249(42.6%) were treated within GINECO and MITO, respectively. 220 patients(37.6%)received surgery inside a reference centre. 528 patients (90.2%) had I stage disease. Surgery was laparoscopic for 229 patients(39.1%). Conservative surgery was performed in 255 cases(43.6%).Peritoneal staging was done in 345 cases(59%). After a median follow up time of 76 months(range 1–657),5- year DFS and OS were 78% and 98%, respectively. At multivariate analysis, independent prognostic factors for improved DFS were early stage [OR 0.44–95% CI 0.29–0.66], optimal cytoreduction[OR 2.75–95% CI 1.32–5.75], radical surgery [OR 0.62–95% CI 0.43–0.87] and management in a reference centre[OR 0.75–95% CI 0.57–0.97]. For OS, only early stage retained significance[0.34–95%CI 0.15–0.78]. Surgical approach, peritoneal staging and adjuvant chemotherapy were not associated with improved survival in I stage disease.

Conclusion Anonymized data pooling from existing registries was feasible. Management in a reference centre, stage, surgical radicality and residual tumor are the only independent prognostic factors for DFS. Early stage only retains significance as prognostic factor for OS. This experience paves the way for further investigations within the ENGOT Rare Tumor Network.

Disclosures No disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.